Literature DB >> 21098034

Insulin-degrading enzyme modulates the natriuretic peptide-mediated signaling response.

Luis A Ralat1, Qing Guo, Min Ren, Todd Funke, Deborah M Dickey, Lincoln R Potter, Wei-Jen Tang.   

Abstract

Natriuretic peptides (NPs) are cyclic vasoactive peptide hormones with high therapeutic potential. Three distinct NPs (ANP, BNP, and CNP) can selectively activate natriuretic peptide receptors, NPR-A and NPR-B, raising the cyclic GMP (cGMP) levels. Insulin-degrading enzyme (IDE) was found to rapidly cleave ANP, but the functional consequences of such cleavages in the cellular environment and the molecular mechanism of recognition and cleavage remain unknown. Here, we show that reducing expression levels of IDE profoundly alters the response of NPR-A and NPR-B to the stimulation of ANP, BNP, and CNP in cultured cells. IDE rapidly cleaves ANP and CNP, thus inactivating their ability to raise intracellular cGMP. Conversely, reduced IDE expression enhances the stimulation of NPR-A and NPR-B by ANP and CNP, respectively. Instead of proteolytic inactivation, IDE cleavage can lead to hyperactivation of BNP toward NPR-A. Conversely, decreasing IDE expression reduces BNP-mediated signaling. Additionally, the cleavages of ANP and BNP by IDE render them active with NPR-B and a reduction of IDE expression diminishes the ability of ANP and BNP to stimulate NPR-B. Our kinetic and crystallographic analyses offer the molecular basis for the selective degradation of NPs and their variants by IDE. Furthermore, our studies reveal how IDE utilizes its catalytic chamber and exosite to engulf and bind up to two NPs leading to biased stochastic, non-sequential cleavages and the ability of IDE to switch its substrate selectivity. Thus, the evolutionarily conserved IDE may play a key role in modulating and reshaping the strength and duration of NP-mediated signaling.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21098034      PMCID: PMC3039328          DOI: 10.1074/jbc.M110.173252

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  31 in total

1.  Degradation of atrial natriuretic peptide: pharmacologic effects of protease EC 24.11 inhibition.

Authors:  R L Webb; G D Yasay; C McMartin; R B McNeal; M B Zimmerman
Journal:  J Cardiovasc Pharmacol       Date:  1989-08       Impact factor: 3.105

2.  Cellular mechanisms of the clearance function of type C receptors of atrial natriuretic factor.

Authors:  D R Nussenzveig; J A Lewicki; T Maack
Journal:  J Biol Chem       Date:  1990-12-05       Impact factor: 5.157

3.  Respective roles of kallikrein and endopeptidase 24.11 in the metabolic pathway of atrial natriuretic peptide in the rat.

Authors:  Y Vanneste; S Pauwels; L Lambotte; A Michel; R Dimaline; M Deschodt-Lanckman
Journal:  Biochem J       Date:  1990-08-01       Impact factor: 3.857

4.  Partial characterization of a metalloendopeptidase activity produced by cultured endothelial cells that removes the COOH-terminal tripeptide from 125I-atrial natriuretic factor.

Authors:  G R Johnson; C J Foster
Journal:  Biochem Biophys Res Commun       Date:  1990-02-28       Impact factor: 3.575

5.  A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor.

Authors:  M Chinkers; D L Garbers; M S Chang; D G Lowe; H M Chin; D V Goeddel; S Schulz
Journal:  Nature       Date:  1989-03-02       Impact factor: 49.962

6.  Urodilatin, a natriuretic factor from kidneys, can modify renal and cardiovascular function in men.

Authors:  H Saxenhofer; A Raselli; P Weidmann; W G Forssmann; A Bub; P Ferrari; S G Shaw
Journal:  Am J Physiol       Date:  1990-11

7.  Molecular basis for the recognition and cleavages of IGF-II, TGF-alpha, and amylin by human insulin-degrading enzyme.

Authors:  Qing Guo; Marika Manolopoulou; Yao Bian; Alexander B Schilling; Wei-Jen Tang
Journal:  J Mol Biol       Date:  2009-11-05       Impact factor: 5.469

8.  Insulin degradation products from perfused rat kidney.

Authors:  W C Duckworth; F G Hamel; J Liepnieks; D Peavy; B Frank; R Rabkin
Journal:  Am J Physiol       Date:  1989-02

9.  Metabolism of 125I-atrial natriuretic factor by vascular smooth muscle cells. Evidence for a peptidase that specifically removes the COOH-terminal tripeptide.

Authors:  G R Johnson; L Arik; C J Foster
Journal:  J Biol Chem       Date:  1989-07-15       Impact factor: 5.157

10.  Substrate activation of insulin-degrading enzyme (insulysin). A potential target for drug development.

Authors:  Eun-Suk Song; Maria Aparecida Juliano; Luiz Juliano; Louis B Hersh
Journal:  J Biol Chem       Date:  2003-10-02       Impact factor: 5.157

View more
  28 in total

Review 1.  Targeting Insulin-Degrading Enzyme to Treat Type 2 Diabetes Mellitus.

Authors:  Wei-Jen Tang
Journal:  Trends Endocrinol Metab       Date:  2015-12-02       Impact factor: 12.015

Review 2.  Rationale and therapeutic opportunities for natriuretic peptide system augmentation in heart failure.

Authors:  Paul M McKie; John C Burnett
Journal:  Curr Heart Fail Rep       Date:  2015-02

3.  Pro-B-type natriuretic peptide-1-108 processing and degradation in human heart failure.

Authors:  Brenda K Huntley; Sharon M Sandberg; Denise M Heublein; S Jeson Sangaralingham; John C Burnett; Tomoko Ichiki
Journal:  Circ Heart Fail       Date:  2014-10-22       Impact factor: 8.790

Review 4.  BNP molecular forms and processing by the cardiac serine protease corin.

Authors:  Tomoko Ichiki; Brenda K Huntley; John C Burnett
Journal:  Adv Clin Chem       Date:  2013       Impact factor: 5.394

5.  Current Understanding of the Compensatory Actions of Cardiac Natriuretic Peptides in Cardiac Failure: A Clinical Perspective.

Authors:  Noel S Lee; Lori B Daniels
Journal:  Card Fail Rev       Date:  2016-05

6.  The insulin-degrading enzyme is an allosteric modulator of the 20S proteasome and a potential competitor of the 19S.

Authors:  Diego Sbardella; Grazia R Tundo; Andrea Coletta; Julien Marcoux; Efthymia Ioanna Koufogeorgou; Chiara Ciaccio; Anna M Santoro; Danilo Milardi; Giuseppe Grasso; Paola Cozza; Marie-Pierre Bousquet-Dubouch; Stefano Marini; Massimo Coletta
Journal:  Cell Mol Life Sci       Date:  2018-03-28       Impact factor: 9.261

7.  ProBNP(1-108) is resistant to degradation and activates guanylyl cyclase-A with reduced potency.

Authors:  Deborah M Dickey; Lincoln R Potter
Journal:  Clin Chem       Date:  2011-07-18       Impact factor: 8.327

Review 8.  M-atrial natriuretic peptide: a novel antihypertensive protein therapy.

Authors:  Paul M McKie; Tomoko Ichiki; John C Burnett
Journal:  Curr Hypertens Rep       Date:  2012-02       Impact factor: 5.369

Review 9.  Natriuretic peptide metabolism, clearance and degradation.

Authors:  Lincoln R Potter
Journal:  FEBS J       Date:  2011-04-07       Impact factor: 5.542

10.  Structure-activity relationships of imidazole-derived 2-[N-carbamoylmethyl-alkylamino]acetic acids, dual binders of human insulin-degrading enzyme.

Authors:  Julie Charton; Marion Gauriot; Jane Totobenazara; Nathalie Hennuyer; Julie Dumont; Damien Bosc; Xavier Marechal; Jamal Elbakali; Adrien Herledan; Xiaoan Wen; Cyril Ronco; Helene Gras-Masse; Antoine Heninot; Virginie Pottiez; Valerie Landry; Bart Staels; Wenguang G Liang; Florence Leroux; Wei-Jen Tang; Benoit Deprez; Rebecca Deprez-Poulain
Journal:  Eur J Med Chem       Date:  2014-12-04       Impact factor: 6.514

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.